We had a chance to catch up with George Lundberg, MD, former JAMA Editor in Chief of JAMA, current Editor-at-Large of Medscape, and now Chief Medical Officer and Editor-in-Chief of CollabRx. CollabRx is a publicly-traded for-profit San Francisco-based data analytics company that does applied oncogenomics. According to George, his company “deals with molecular changes in cancers and tries to help doctors [find] the best targeted therapies for patients with advanced cancers or cancers that are capable of becoming advanced.” They have two main products: Cancer Rx and a Genetic Variant Annotation (GVA) Service. CollabRx is perfectly situated to help clinicians and patients benefit from the explosion precision medicine tools.

And as George put it, “The field of precision medicine is booming. The conference we are, Personalized Medicine World Conference, started 9 years ago with 30 people. This year, there were over a thousand and some people had to be turned away. The conference was sold out. There’s hype, there’s hope, a little bit of both, but very vibrant science.” To learn more, watch the video.

Read more here: http://thedoctorweighsin.com/collabrx-applied-oncogenomics-for-doctors-patients/.

This video was filmed at the Personalized Medicine World Conference in Mountain View, California in January 2014.

This video is under BY-ND creative commons.